CRVS — Corvus Pharmaceuticals, Inc.

Summary of Corvus Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Financials:
  • Research and Development (R&D) expenses increased to $9.9 million from $6 million in Q4 2024.
  • Full year R&D expenses rose to $33.7 million from $19.4 million in 2024.
  • Net loss for Q4 2025 was $12.3 million, slightly up from $12.1 million in Q4 2024.
  • Cash, cash equivalents, and marketable securities totaled $56.8 million as of December 31, 2025, up from $52 million a year prior.
  • Following a public offering, pro forma cash is approximately $246 million, extending the cash runway into Q2 2028.

2. Strategic Updates and Business Highlights

• Clinical Progress: Significant advancements in the development of soquelitinib, a selective ITK inhibitor. Key highlights include:

  • Positive results from Phase I/Ib trials in peripheral T-cell lymphoma (PTCL) and atopic dermatitis.
  • Initiation of a Phase II trial for atopic dermatitis with plans to enroll 200 patients.
  • Ongoing enrollment in a Phase III PTCL trial, with an interim analysis expected later this year.
  • Plans to expand trials into hidradenitis suppurativa and asthma later in 2026.

• Efficacy and Safety: Soquelitinib demonstrated a strong efficacy profile in atopic dermatitis, with 75% of patients achieving EASI 75 after 8 weeks of treatment. The drug showed durability of response with no disease rebound observed post-treatment.

3. Forward Guidance and Outlook

• Corvus is optimistic about the potential of soquelitinib across multiple indications, including atopic dermatitis and PTCL.
• The company anticipates ongoing enrollment in clinical trials and expects to report additional data from the Phase II atopic dermatitis trial in mid-2027.
• The upcoming data from the Angel Pharmaceuticals trial in China and interim results from the PTCL trial are expected to provide further insights into the drug's efficacy and safety.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The company faces competition from established therapies in atopic dermatitis and PTCL, which may impact market penetration.
• Data Acceptance: A late-breaker abstract for the AAD meeting was not accepted, raising concerns about visibility and acceptance within the scientific community.
• Clinical Trial Risks: The reliance on ongoing clinical trials for future success poses inherent risks, including potential delays in data readouts and the need for continued funding.

5. Notable Q&A Insights

• Management addressed questions regarding the read-through from upcoming data readouts, emphasizing the importance of the Angel Pharmaceuticals trial data and the PTCL interim analysis.
• Discussions highlighted the durability of response in patients treated with soquelitinib, with over 90% maintaining response at 3 months post-treatment.
• The company is considering the inclusion of patients with both asthma and atopic dermatitis in future studies, although regulatory pathways for dual indications remain complex.
• Management expressed confidence in the drug's mechanism of action and its potential to treat multiple inflammatory diseases, despite challenges in establishing predictive models for certain conditions like hidradenitis suppurativa.

Overall, Corvus Pharmaceuticals is positioned with a strong cash runway and promising clinical data, but it must navigate competitive pressures and the uncertainties inherent in clinical development.